172 related articles for article (PubMed ID: 35316324)
1. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
Passet M; Kim R; Gachet S; Sigaux F; Chaumeil J; Galland A; Sexton T; Quentin S; Hernandez L; Larcher L; Bergugnat H; Ye T; Karasu N; Caye A; Heizmann B; Duluc I; Chevallier P; Rousselot P; Huguet F; Leguay T; Hunault M; Pflumio F; Freund JN; Lobry C; Lhéritier V; Dombret H; Domon-Dell C; Soulier J; Boissel N; Clappier E
Blood; 2022 Jun; 139(24):3505-3518. PubMed ID: 35316324
[TBL] [Abstract][Full Text] [Related]
2. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Kimura S; Montefiori L; Iacobucci I; Zhao Y; Gao Q; Paietta EM; Haferlach C; Laird AD; Mead PE; Gu Z; Stock W; Litzow M; Rowe JM; Luger SM; Hunger SP; Ryland GL; Schmidt B; Ekert PG; Oshlack A; Grimmond SM; Rehn J; Breen J; Yeung D; White DL; Aldoss I; Jabbour EJ; Pui CH; Meggendorfer M; Walter W; Kern W; Haferlach T; Brady S; Zhang J; Roberts KG; Blombery P; Mullighan CG
Blood; 2022 Jun; 139(24):3519-3531. PubMed ID: 35192684
[TBL] [Abstract][Full Text] [Related]
3. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment.
Bastian L; Hartmann AM; Beder T; Hänzelmann S; Kässens J; Bultmann M; Hoeppner MP; Franzenburg S; Wittig M; Franke A; Nagel I; Spielmann M; Reimer N; Busch H; Schwartz S; Steffen B; Viardot A; Döhner K; Kondakci M; Wulf G; Wendelin K; Renzelmann A; Kiani A; Trautmann H; Neumann M; Gökbuget N; Brüggemann M; Baldus CD
Leukemia; 2022 Jun; 36(6):1676-1680. PubMed ID: 35397658
[No Abstract] [Full Text] [Related]
4. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T; Sanada M; Kawazu M; Kojima S; Tsuzuki S; Ueno H; Iwamoto E; Iijima-Yamashita Y; Yamada T; Kanamori T; Nishimura R; Kuwatsuka Y; Takada S; Tanaka M; Ota S; Dobashi N; Yamazaki E; Hirose A; Murayama T; Sumi M; Sato S; Tange N; Nakamura Y; Katsuoka Y; Sakaida E; Kawamata T; Iida H; Shiraishi Y; Nannya Y; Ogawa S; Taniwaki M; Asou N; Hatta Y; Kiyoi H; Matsumura I; Horibe K; Mano H; Naoe T; Miyazaki Y; Hayakawa F
Blood; 2022 Mar; 139(12):1850-1862. PubMed ID: 34695176
[TBL] [Abstract][Full Text] [Related]
5. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
6. CDX2 gene expression in acute lymphoblastic leukemia.
Arnaoaut HH; Mokhtar DA; Samy RM; Khames SA; Omar SA
J Egypt Natl Canc Inst; 2014 Jun; 26(2):55-9. PubMed ID: 24841154
[TBL] [Abstract][Full Text] [Related]
7. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia.
Thoene S; Rawat VP; Heilmeier B; Hoster E; Metzeler KH; Herold T; Hiddemann W; Gökbuget N; Hoelzer D; Bohlander SK; Feuring-Buske M; Buske C
Leukemia; 2009 Apr; 23(4):649-55. PubMed ID: 19158837
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia.
Riedt T; Ebinger M; Salih HR; Tomiuk J; Handgretinger R; Kanz L; Grünebach F; Lengerke C
Blood; 2009 Apr; 113(17):4049-51. PubMed ID: 19218548
[TBL] [Abstract][Full Text] [Related]
9. The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia.
Urbańska Z; Lejman M; Taha J; Madzio J; Ostrowska K; Miarka-Walczyk K; Wypyszczak K; Styka B; Jakubowska J; Sędek Ł; Szczepański T; Stańczak M; Fendler W; Młynarski W; Pastorczak A
Neoplasia; 2023 Jan; 35():100840. PubMed ID: 36288679
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of CDX2 in leukemia: A new perspective for leukemia research.
Darvishi M; Mashati P; Khosravi A
Leuk Res; 2018 Sep; 72():45-51. PubMed ID: 30096576
[TBL] [Abstract][Full Text] [Related]
11. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value.
Codrington R; O'Connor HE; Jalali GR; Carrara P; Papaioannou M; Hart SM; Hoffbrand AV; Potter M; Prentice HG; Harrison CJ; Foroni L
Br J Haematol; 2000 Dec; 111(4):1071-9. PubMed ID: 11167742
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of caudal type homeobox transcription factor-2 in adult acute lymphocytic leukemia].
Lu HY; Xia HL; Chen XW; Zhu LX; Wang QY; Cheng X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):298-302. PubMed ID: 21518475
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
16. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
17. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
[TBL] [Abstract][Full Text] [Related]
20. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
Yang M; Safavi S; Woodward EL; Duployez N; Olsson-Arvidsson L; Ungerbäck J; Sigvardsson M; Zaliova M; Zuna J; Fioretos T; Johansson B; Nord KH; Paulsson K
Blood; 2020 Aug; 136(8):946-956. PubMed ID: 32384149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
